Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
Claire F. Friedman(Memorial Sloan Kettering Cancer Center), Dmitriy Zamarin(Cornell University)
Cited by 25
Related Papers
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
|Journal of Clinical Investigation|2018|148